Diabetic Retinopathy

According to the company, GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals.

While it fell short of the primary endpoint of improvement of non-proliferative diabetic retinopathy (NPDR) of at least 2 Diabetic Retinopathy Severity Scale (DRSS) levels as of week 36, DURAVYU did demonstrate stable or improved disease severity with reduced rates of NPDR in 9 months.

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy.

Data will be shared in early 2024 regarding this potential treatment of diabetic retinopathy via eye drop.

EURETINA 2023 highlighted important DME and DR research and data from across the globe.

Researchers are addressing growing concern over vision loss in people taking semaglutideat the American Academy of Ophthalmology annual meeting in San Francisco.

The company made this decision after completing phase 2 trials of the drug.

This effort will advance screening technology at Canada’s foremost specialist care provider in diabetes and endocrinology.

A new survey shows that 95% of adults at risk for certain retinal diseases know a little or nothing about them. Allen hopes her story will help raise awareness and encourage those at risk to regularly prioritize their eye health.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.

Lim and colleagues conducted a retrospective study to establish the normalized NBFI using OCTA and test if that index is sufficiently sensitive for detecting early DR.

APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy.

The DR:EAM trial will evaluate topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

This partnership will allow IRIS to license AEYE Diagnostic Screening (AEYE-DS), an FDA-cleared AI technology for autonomous detection of diabetic retinopathy (DR).

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

A new study titled, “Prevalence of Diabetic Retinopathy in the US in 2021,” finds that almost 10 million people in the United States with diabetes have diabetic retinopathy.

Gonzalez shared that the ZETA-1 trial results demonstrate the potential of APX3330 to slow disease progression as well as highlight its favorable safety profile in the diabetic patient population.

The study's findings demonstrate the accuracy and feasibility of using machine learning models for identifying diabetic retinopathy (DR) progression developed using UWF images.

The certification will allow 20/20 Onsite to make clinical trials more accessible to patients nationwide and expand site options for sponsors while maintaining performance and data collection standards, including BCVA and DR testing.

OTX-TKI is the Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

PAVIA is a 12-month, randomized, controlled phase 2 clinical trial of EYP-1901 in patients with moderate to severe NPDR.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

Eyetelligence will offer non-invasive point-of-care technology to diagnose a range of diseases, including diabetic retinopathy and age-related macular degeneration, with AI algorithmic retinal image analysis.

A study by Verana Health shows how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps.

The study results show the potential of SREDs to treat progressive, chronic retina conditions including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).